Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Authors: Yann Vano, Réza Elaidi, Mostefa Bennamoun, Christine Chevreau, Delphine Borchiellini, Diane Pannier, Denis Maillet, Marine Gross‐Goupil, Christophe Tournigand, Brigitte Laguerre, Philippe Barthélémy, Elodie Coquan, Gwénaëlle Gravis, Nadine Houédé, Mathilde Cancel, Olivier Huillard, Philippe Beuzeboc, Laure Fournier, Arnaud Méjean, Xavier Cathelineau, N. Doumerc, P. Paparel, Jean‐Christophe Bernhard, Alexandre de la Taille, Karim Bensalah, Thibault Tricard, Thibaut Waeckel, G. Pignot, E. Braychenko, Stefano Caruso, Cheng‐Ming Sun, Virginie Verkarre, Guillaume Lacroix, Marco Moreira, Maxime Meylan, Antoine Bougoüin, Letuan Phan, Christelle Thibault-Carpentier, Jessica Zucman‐Rossi, Wolf H. Fridman, Catherine Sautès‐Fridman, Stéphane Oudard - The Lancet 2022 cited by 136